Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...

Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

Further, 33.2% of patients on the highest semaglutide dose achieved weight loss of at least 25% after the 72-week mark, versus 16.7% of patients on semaglutide 2.4 mg and 0% of patients on placebo ...

By harnessing the power of semaglutide, GetSimpli provides a natural approach to weight loss that goes beyond traditional ... to follow the recommended dosage and consult with healthcare ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more than 40 years, but says when so called GLP-1 drugs made from semaglutide ...

Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72. Topline data were announced from a phase 3b trial evaluating ...